DIFFERENCES IN PLASMA-BINDING OF DRUGS BETWEEN CAUCASIANS AND CHINESE SUBJECTS

被引:68
作者
ZHOU, HH [1 ]
ADEDOYIN, A [1 ]
WILKINSON, GR [1 ]
机构
[1] VANDERBILT UNIV,MED CTR,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232
关键词
D O I
10.1038/clpt.1990.111
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Interracial differences in drug responsiveness can be accounted for, at least in part, by differences in drug disposition. To investigate whether reversible interactions with plasma constituents may be a contributing factor in such differences, the binding of a number of model drugs was studied in plasma obtained from healthy Caucasian and Chinese subjects (n = 8 in each group). The unbound fractions of drugs binding to sites I and II on albumin (warfarin, diazepam, and salicylic acid) were similar in the two groups, and there was no difference in the plasma albumin concentration. By contrast, the percentages of unbound diphenhydramine (26.40% ± 6.46% versus 18.30% ± 4.31, mean ± SD) and propranolol (13.81% ± 1.33% versus 11.68% ± 2.37) were significantly (p < 0.05) higher in Chinese subjects compared to Caucasians. A 30% difference was also observed in the nonlinear binding of disopyramide. These basic drugs interact with both α1-acid glycoprotein and albumin, and the lower binding was associated with a lower plasma concentration of the acute-phase reactant in Chinese subjects. Kinetic analysis of the disopyramide binding isotherm was also suggestive of reduced binding capacity with no change in binding affinity. The reason for the racial difference in the α1-acid glycoprotein level is unknown; however, for drugs extensively bound to this glycoprotein the resulting difference in unbound fraction would be expected to have predictable pharmacokinetic consequences that may result in differences in responsiveness. Determination of plasma binding, especially of drugs interacting with α1-add glycoprotein, should therefore be an essential component of comparative studies in subjects of different races. © 1990.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 16 条
  • [1] FAMILY STUDY OF GENETIC AND ENVIRONMENTAL-FACTORS DETERMINING THE PROTEIN-BINDING OF PROPRANOLOL
    ALVAN, G
    BERGSTROM, K
    BORGA, O
    ISELIUS, L
    PEDERSEN, N
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 25 (04) : 437 - 441
  • [2] PLASMA-BINDING OF DISOPYRAMIDE
    DAVID, BM
    MADSEN, BW
    ILETT, KF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (06) : 614 - 618
  • [3] Eap C B, 1989, Prog Clin Biol Res, V300, P111
  • [4] KALOW W, 1986, PROGR CLIN BIOL RES, V214, P583
  • [5] KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17
  • [6] KREMER JMH, 1988, PHARMACOL REV, V40, P1
  • [7] DIFFERENCES IN DIAZEPAM PHARMACOKINETICS IN CHINESE AND WHITE CAUCASIANS - RELATION TO BODY LIPID STORES
    KUMANA, CR
    LAUDER, IJ
    CHAN, M
    KO, W
    LIN, HJ
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 32 (02) : 211 - 215
  • [8] Mancini G, 1965, IMMUNOCHEMISTRY, V2, P235
  • [9] HALOPERIDOL CONCENTRATIONS ELEVATED IN CHINESE PATIENTS
    POTKIN, SG
    SHEN, YC
    PARDES, H
    PHELPS, BH
    ZHOU, DF
    SHU, LN
    KORPI, E
    WYATT, RJ
    [J]. PSYCHIATRY RESEARCH, 1984, 12 (02) : 167 - 172
  • [10] RODKEY FL, 1965, CLIN CHEM, V11, P478